A study reveals for the first time the effects of three available treatments for SMA on the cognitive profile of infants with SMA type I:
- 18 infants participated in the study, 11 SMA type I treated post-symptomatically and 7 presymptomatically,
- 11 received Spinraza, three received Evrysdi and four received Zolgensma,
- In the presymptomatically treated infants, the cognitive score was mean, and for one of them, lower than the mean,
- the cognitive score of those treated post-symptomatically was rather below the mean, with a tendency to improve during the three years of follow-up.
The authors conclude that the cognitive profile should also be taken into account when treating patients with type I SMA.
